hotspot -WSS

hotspot

author：explore 2025-08-28 13:04:28 - browse：82529

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Readout Newsletter: Amgen, Regeneron, BGI Group and more

hotspot

focus

WSS

FDA panel endorses Alnylam’s heart drug — after picking it apart

Surgery pushed Ben Carson to fame

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Devoted Health’s losses in Medicare Advantage persist

Acelyrin, a rare IPO success, stumbles in its first big test

A protest over insulin prices is seen as a fight for life

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Virginia high school admissions case could be legal follow

Walmart eyes Medicare Advantage provider ChenMed

Hollywood unions extend contract negotiations for actors

Gene therapy for Afghan refugees’ infant will be fully covered

Apple is now the first public company to be valued at $3 trillion

Acelyrin, a rare IPO success, stumbles in its first big test

In Memoriam: Notable people who died in 2023

FDA proposes changes to key medical devices approval pathway

ChatGPT in medicine: STAT answers readers' burning questions

AstraZeneca stays mum on Medicare drug pricing negotiations

focus

340B reform proposal comes out of Senate working group

Nick Leschly quits Bluebird Bio spinout amid restructuring, layoffs

Problems with a popular proposal to regulate AI in health care

Pig kidney works a record two months in donated body

Updated Covid vaccine has 54% effectiveness, new study suggests

Updated Covid vaccine has 54% effectiveness, new study suggests

hotspot

leisure time

focus

knowledge